BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36924851)

  • 1. SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma.
    Li Z; Liao X; Hu Y; Li M; Tang M; Zhang S; Mo S; Li X; Chen S; Qian W; Feng R; Yu R; Xu Y; Yuan S; Xie C; Li J
    Free Radic Biol Med; 2023 May; 201():41-54. PubMed ID: 36924851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.
    Xu FL; Wu XH; Chen C; Wang K; Huang LY; Xia J; Liu Y; Shan XF; Tang N
    Cell Death Dis; 2023 Jan; 14(1):22. PubMed ID: 36635256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
    Li Y; Yang W; Zheng Y; Dai W; Ji J; Wu L; Cheng Z; Zhang J; Li J; Xu X; Wu J; Yang M; Feng J; Guo C
    J Exp Clin Cancer Res; 2023 Jan; 42(1):6. PubMed ID: 36604718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis.
    Hsu TW; Su YH; Chen HA; Liao PH; Shen SC; Tsai KY; Wang TH; Chen A; Huang CY; Shibu MA; Wang WY; Shen SC
    Aging (Albany NY); 2023 Jul; 15(13):6503-6525. PubMed ID: 37433225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solute Carrier Family 27 Member 4 (SLC27A4) Enhances Cell Growth, Migration, and Invasion in Breast Cancer Cells.
    Yen MC; Chou SK; Kan JY; Kuo PL; Hou MF; Hsu YL
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30388870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation.
    Shi Z; Li Z; Jin B; Ye W; Wang L; Zhang S; Zheng J; Lin Z; Chen B; Liu F; Zhang B; Ding X; Yang Z; Shan Y; Yu Z; Wang Y; Chen J; Chen Q; Roberts LR; Chen G
    Clin Transl Med; 2023 Jun; 13(6):e1300. PubMed ID: 37337470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC.
    Gao Q; Zhang G; Zheng Y; Yang Y; Chen C; Xia J; Liang L; Lei C; Hu Y; Cai X; Zhang W; Tang H; Chen Y; Huang A; Wang K; Tang N
    Cell Death Differ; 2020 Mar; 27(3):1086-1104. PubMed ID: 31367013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway.
    Ji J; Cheng Z; Zhang J; Wu J; Xu X; Guo C; Feng J
    J Cell Mol Med; 2024 Apr; 28(8):e18335. PubMed ID: 38652216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis.
    Li T; Huang HY; Qian B; Wang WH; Yuan Q; Zhang HY; He J; Ni KJ; Wang P; Zhao ZY; He JL; Fu SW; Xu L; Lin YC; Lin ZN
    Free Radic Biol Med; 2024 Feb; 212():360-374. PubMed ID: 38171407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma.
    Huang CY; Chen LJ; Chen G; Chao TI; Wang CY
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.
    Lu Z; Yang H; Shao Y; Sun W; Jiang Y; Li J
    Biochem Biophys Res Commun; 2022 Oct; 627():103-110. PubMed ID: 36030651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma.
    Zhang L; Li XM; Shi XH; Ye K; Fu XL; Wang X; Guo SM; Ma JQ; Xu FF; Sun HM; Li QQ; Zhang WY; Ye LH
    Acta Pharmacol Sin; 2023 Mar; 44(3):622-634. PubMed ID: 36109580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma.
    Hao SH; Ma XD; Xu L; Xie JD; Feng ZH; Chen JW; Chen RX; Wang FW; Tang YH; Xie D; Cai MY
    Drug Resist Updat; 2024 Mar; 73():101052. PubMed ID: 38262246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3.
    Hu Z; Zhao Y; Li L; Jiang J; Li W; Mang Y; Gao Y; Dong Y; Zhu J; Yang C; Ran J; Li L; Zhang S
    Mol Biol Rep; 2023 Aug; 50(8):6399-6413. PubMed ID: 37326750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
    Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y
    J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma.
    Byun JK; Lee S; Kang GW; Lee YR; Park SY; Song IS; Yun JW; Lee J; Choi YK; Park KG
    J Exp Clin Cancer Res; 2022 Mar; 41(1):98. PubMed ID: 35287706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma.
    Huang W; Chen K; Lu Y; Zhang D; Cheng Y; Li L; Huang W; He G; Liao H; Cai L; Tang Y; Zhao L; Pan M
    Neoplasia; 2021 Dec; 23(12):1227-1239. PubMed ID: 34768109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
    Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
    Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.